Medtronic SynchroMed Legal News Articles & Interviews

Sacramento, CA: A Medtronic SynchroMed Infusion pump lawsuit brought by a plaintiff who without doubt suffered as the result of an allegedly defective medical device, saw his case lost due to legal precedent and various legal roadblocks that preempted his claims and assertions under a Medical Device Amendment (MDA) to the Food, Drug, and Cosmetic Act (FDCA).

Harrisburg, PA: The dog-eared adage suggesting ‘there is a place for everything, and everything in its place’ certainly applies to marketing undertaken by the pharmaceutical and medical device communities: witness television commercials expounding upon the virtues of a drug, only to have a litany of potentially serious side effects narrated by a nonetheless welcoming voice amidst pleasant music and comforting scenes. Similarly, medical device manufacturers duly note the shortcomings of their devices on their websites, but only after you land on the home page that boasts the virtues of their product. Meanwhile, the plaintiff filing the Medtronic SynchroMed lawsuit, for example, shakes his head as he recalls the time the life-saving device allegedly landed him in the hospital.

Washington, DC: The honeymoon the then-fresh Obama Administration was still largely enjoying in 2010 was nonetheless tainted two years into Barack Obama’s Presidency with revelations that hundreds of Americans supposedly had died due to malfunctioning infusion pumps. The Medtronic SynchroMed pump was among the plethora of infusion pumps that were coming under increased scrutiny by the US Food and Drug Administration (FDA) at the time.

Tucson, AZ: Medtronic devices which have been around since 1988 and 1999 respectively have been the focus of much scrutiny in recent years, with the most recent concern landing earlier this year with a Class 1 recall related to software associated with the SynchroMed Implantable Infusion Pump. A Class 1 recall, about which anyone considering a Medtronic SynchroMed recall lawsuit would appreciate knowing, is the most serious of the three recall classifications maintained by the US Food and Drug Administration (FDA).

New York, NY The US Food and Drug Administration (FDA) announced that it is requiring makers of infusion pumps to provide more test data before those pumps can be approved to go on the market. The announcement was made because of concerns about the safety of infusion pumps.